<?xml version="1.0" encoding="UTF-8"?>
<p id="para510">Despite the absence of international consensus on the gold-standard therapy for previously untreated patients with peripheral T-cell lymphoma, CHOP has been adopted by many countries as the reference regimen.
 <xref rid="bib25" ref-type="bibr">
  <sup>25</sup>
 </xref> With the exception of ALK-positive anaplastic large cell T-cell lymphoma
 <xref rid="bib26" ref-type="bibr">
  <sup>26</sup>
 </xref> the outcomes with CHOP or CHOP-like therapy appear to be suboptimum, with a 5-year overall survival of only 38·5%, as reported in a meta-analysis.
 <xref rid="bib5" ref-type="bibr">
  <sup>5</sup>
 </xref> Attempts to surpass outcomes with CHOP have proven largely unsuccessful, except a subgroup analysis by the German High-Grade NHL Study Group that showed improved event-free survival but no overall survival benefit with CHOEP for younger patients (≤60 years) with peripheral T-cell lymphoma with normal lactate dehydrogenase concentrations treated within aggressive non-Hodgkin lymphoma clinical trials.
 <xref rid="bib6" ref-type="bibr">
  <sup>6</sup>
 </xref> Therefore, optimising therapy for newly diagnosed patients remains an important unmet medical need.
</p>
